Desmopressin Mechanism of Action

Mechanism of Action of Desmopressin

by

Introduction

Desmopressin (1-deamino-8-D-arginine vasopressin; DDAVP) is a synthetic analogue of the natural antidiuretic hormone vasopressin. It exhibits strong antidiuretic properties with minimal vasopressor activity, which makes it an effective and safer alternative in treating disorders involving water balance and bleeding diatheses. Its high affinity for V2 receptors and negligible action on V1 receptors differentiates it from native vasopressin, allowing selective therapeutic utility.

Mechanism of Action (Step-wise)

  1. Binding to V2 Receptors
    Desmopressin selectively binds to vasopressin V2 receptors located in the renal collecting ducts.
  2. Gs Protein Activation
    V2 receptor activation engages Gs protein, stimulating adenylyl cyclase.
  3. Increased cAMP Production
    The intracellular rise in cyclic AMP (cAMP) leads to activation of protein kinase A (PKA).
  4. Aquaporin-2 Phosphorylation
    PKA phosphorylates aquaporin-2 (AQP2) water channel proteins.
  5. Membrane Insertion of Aquaporins
    Phosphorylated AQP2 channels are translocated and inserted into the apical membrane of renal epithelial cells.
  6. Water Reabsorption Enhancement
    Water is reabsorbed from tubular fluid back into the bloodstream, concentrating the urine and reducing diuresis.
  7. Hemostatic Action
    Desmopressin also stimulates endothelial release of von Willebrand factor (vWF), factor VIII, and tissue plasminogen activator (tPA), useful in patients with bleeding tendencies such as mild hemophilia A and type 1 von Willebrand disease.
Desmopressin Mechanism of Action
Mechanism of action of Desmopressin
Desmopressin Mechanism of Action flowchart
Mechanism of action of Desmopressin flowchart

Pharmacokinetics

  • Routes: Oral, intranasal, intravenous, subcutaneous
  • Oral Bioavailability: 0.1–0.2%
  • Intranasal Bioavailability: 3–5%
  • Peak Plasma Time: 1–2 hours (oral), 30–60 minutes (intranasal)
  • Plasma Half-Life: 2–4 hours
  • Metabolism: Hepatic and renal
  • Excretion: Primarily renal as inactive metabolites

Clinical Uses

  • Central Diabetes Insipidus (CDI)
  • Primary nocturnal enuresis
  • Nocturia due to nocturnal polyuria
  • Mild hemophilia A and von Willebrand disease (type 1)
  • Platelet dysfunction in uremic patients
  • Diagnostic test for differentiating CDI from nephrogenic DI

Adverse Effects

  • Mild Effects: Headache, nausea, nasal irritation (intranasal route), flushing
  • Severe Effects: Water intoxication, hyponatremia, seizures
  • Precautions: Sodium monitoring in children and elderly
  • Contraindications: Hyponatremia, moderate to severe renal impairment, SIADH

Comparative Analysis

ParameterDesmopressinVasopressin
Receptor SelectivityV2 selectiveV1 & V2 agonist
Antidiuretic EffectPotentPotent
Vasoconstrictive EffectMinimalProminent
Duration of ActionLongerShorter
Hemostatic ActionYesNo
Use in Bleeding DisordersYesRare

Desmopressin’s improved receptor selectivity and prolonged duration make it a safer and more targeted therapy than vasopressin.

Multiple Choice Questions (MCQs)

  1. Desmopressin acts on which receptor?
    A. V1a
    B. V2
    C. Alpha-1
    D. Beta-1
    Answer: B. V2
  2. A key adverse effect of desmopressin therapy:
    A. Hyponatremia
    B. Hyperkalemia
    C. Tachycardia
    D. Hypertension
    Answer: A. Hyponatremia
  3. Desmopressin enhances the release of all except:
    A. Factor VIII
    B. Tissue plasminogen activator
    C. von Willebrand factor
    D. ADH
    Answer: D. ADH
  4. Desmopressin is contraindicated in:
    A. Type 1 VWD
    B. Nocturnal enuresis
    C. Severe renal impairment
    D. Central diabetes insipidus
    Answer: C. Severe renal impairment
  5. Compared to vasopressin, desmopressin has:
    A. Higher pressor activity
    B. Shorter half-life
    C. Greater V1 selectivity
    D. Minimal vasoconstriction
    Answer: D. Minimal vasoconstriction

FAQs

Q1. What makes desmopressin safer than vasopressin?
Desmopressin lacks vasoconstrictor effects, reducing the risk of cardiovascular side effects.

Q2. How is desmopressin administered for nocturnal enuresis?
Typically via oral tablets 1–2 hours before bedtime.

Q3. Why is sodium monitoring essential with desmopressin?
Because excessive water retention can lead to dilutional hyponatremia and seizures.

Q4. Can desmopressin be used for diagnostic purposes?
Yes, it helps differentiate central from nephrogenic diabetes insipidus.

Q5. Is desmopressin effective in nephrogenic DI?
No, it is ineffective since the kidneys are unresponsive to ADH in nephrogenic DI.

References

  1. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th Edition
  2. KD Tripathi, Essentials of Medical Pharmacology, 7th Edition
  3. British National Formulary (BNF)
  4. FDA Drug Label for Desmopressin Acetate

Leave a Comment